Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia

Neuroscience Research

Volumn 77, Issue 4, 2013, Pages 242-246

  Bézard, Erwan ^a,b,c   Muñoz, Ana ^d   Tronci, Elisabetta ^e   Pioli, Elsa Y ^f   Li, Qin ^c,g   Porras, Gregory ^f   Björklund, Anders ^g   Carta, Manolo ^e  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f Williams House   (United Kingdom)

^g LUND UNIVERSITY   (Sweden)

Author keywords

5 HT1A 1B agonists; 6 OHDA; Dyskinesia; L DOPA; Parkinson's disease; Serotonin

Indexed keywords

ANPIRTOLINE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; EXPERIMENTAL MONKEY; FEMALE; LOCOMOTION; LOW DRUG DOSE; MACACA; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SEROTONINERGIC NERVE CELL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 5-HT1A/1B AGONISTS; 6-HYDROXY-DOPAMINE; 6-OHDA; ABNORMAL INVOLUNTARY MOVEMENTS; AIMS; DA; DOPAMINE; DYSKINESIA; L-DOPA; L-DOPA-INDUCED DYSKINESIA; LID; MPTP; PARKINSON'S DISEASE; PD; SEROTONIN; TH; TYROSINE HYDROXYLASE;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; PARKINSONIAN DISORDERS; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84888362340     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2013.10.002     Document Type: Article

References (28)

1. Arai R., Karasawa N., Geffard M., Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a doublelabeling immunofluorescence study. Neurosci. Lett. 1995, 195:195-198.
2. Arai R., Karasawa N., Geffard M., Nagatsu T., Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 1994, 667:295-299.
3. Aubert I., Guigoni C., Håkansson K., Li Q., Dovero S., Barthe N., Bioulac B.H., Gross C.E., Fisone G., Bloch B., Bézard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
4. 3 receptor function. Nat. Med. 2003, 9:762-767.
5. Bézard E., Imbert C., Deloire X., Bioulac B., Gross C.E. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 1997, 766:107-112.
6. Bézard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov. Disord. 2013, 28:1088-1096.
7. Bishop C., Krolewski D.M., Eskow K.L., Barnum C.J., Dupre K.B., Deak T., Walker P.D. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J. Neurosci. Res. 2009, 87:1645-1658.
8. Carlsson T., Carta M., Winkler C., Björklund A., Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27:8011-8022.
9. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007, 130:1819-1833.
10. Carta M., Carlsson T., Muñoz A., Kirik D., Björklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Mov. Disord. 2010, 25(Suppl 1):S174L 179.
11. Carta M., Carlsson T., Muñoz A., Kirik D., Björklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog. Brain Res. 2008, 172:465-478.
12. Carta M., Bézard E. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 2011, 198:245-251.
13. Dupre K.B., Eskow K.L., Steiniger A., Klioueva A., Negron G.E., Lormand L., Park J.Y., Bishop C. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl) 2008, 199:99-108.
14. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-DOPA-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63:610-620.
15. Fox S.H., Johnston T.H., Li Q., Brotchie J., Bézard E. A critique of available scales and presentation of the non-human primate dyskinesia rating scale. Mov. Disord. 2012, 27:1373-1378.
16. Guigoni C., Dovero S., Aubert I., Li Q., Bioulac B.H., Bloch B., Gurevich E.V., Gross C.E., Bézard E. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur. J. Neurosci. 2005, 22:283-287.
17. Hummel T., Hummel C., Friedel I., Pauli E., Kobal G. A comparison of the antinociceptive effects of imipramine, tramadol and anpirtoline. Br. J. Clin. Pharmacol. 1994, 37:325-333.
18. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
19. Muñoz A., Carlsson T., Tronci E., Kirik D., Björklund A., Carta M. Serotonin neuron-dependent and independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol. 2009, 219:298-307.
20. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bézard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
21. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis. 2010, 38:136-143.
22. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
23. Porras G., Berthet A., Dehay B., Li Q., Ladepeche L., Normand E., Dovero S., Martinez A., Doudnikoff E., Martin-Négrier M.L., Chuan Q., Bloch B., Choquet D., Boué-Grabot E., Groc L., Bézard E. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J. Clin. Invest. 2012, 122:3977-3989.
24. Schlicker E., Werner U., Hamon M., Gozlan H., Nickel B., Szelenyi I., Göthert M. Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with antinociceptive/antidepressant-like actions in rodents. Br. J. Pharmacol. 1992, 105:732-738.
25. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
26. Tronci E., Shin E., Björklund A., Carta M. Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study. Neurosci. Res. 2012, 73:168-172.
27. Ulusoy A., Sahin G., Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13159-13164.
28. Zhang X., Andren P.E., Greengard P., Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2163-2168.